Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

De Novo and Inherited Pathogenic Variants in KDM3B Cause Intellectual Disability, Short Stature, and Facial Dysmorphism.

Diets IJ, van der Donk R, Baltrunaite K, Waanders E, Reijnders MRF, Dingemans AJM, Pfundt R, Vulto-van Silfhout AT, Wiel L, Gilissen C, Thevenon J, Perrin L, Afenjar A, Nava C, Keren B, Bartz S, Peri B, Beunders G, Verbeek N, van Gassen K, Thiffault I, Cadieux-Dion M, Huerta-Saenz L, Wagner M, Konstantopoulou V, Vodopiutz J, Griese M, Boel A, Callewaert B, Brunner HG, Kleefstra T, Hoogerbrugge N, de Vries BBA, Hwa V, Dauber A, Hehir-Kwa JY, Kuiper RP, Jongmans MCJ.

Am J Hum Genet. 2019 Apr 4;104(4):758-766. doi: 10.1016/j.ajhg.2019.02.023. Epub 2019 Mar 28.

2.

TRIM28 haploinsufficiency predisposes to Wilms tumor.

Diets IJ, Hoyer J, Ekici AB, Popp B, Hoogerbrugge N, van Reijmersdal SV, Bhaskaran R, Hadjihannas M, Vasileiou G, Thiel CT, Seven D, Uebe S, Ilencikova D, Waanders E, Mavinkurve-Groothuis AMC, Roeleveld N, de Krijger RR, Wegert J, Graf N, Vokuhl C, Agaimy A, Gessler M, Reis A, Kuiper RP, Jongmans MCJ, Metzler M.

Int J Cancer. 2019 Aug 15;145(4):941-951. doi: 10.1002/ijc.32167. Epub 2019 Feb 14.

PMID:
30694527
3.

High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer.

Diets IJ, Waanders E, Ligtenberg MJ, van Bladel DAG, Kamping EJ, Hoogerbrugge PM, Hopman S, Olderode-Berends MJ, Gerkes EH, Koolen DA, Marcelis C, Santen GW, van Belzen MJ, Mordaunt D, McGregor L, Thompson E, Kattamis A, Pastorczak A, Mlynarski W, Ilencikova D, van Silfhout AV, Gardeitchik T, de Bont ES, Loeffen J, Wagner A, Mensenkamp AR, Kuiper RP, Hoogerbrugge N, Jongmans MC.

Clin Cancer Res. 2018 Apr 1;24(7):1594-1603. doi: 10.1158/1078-0432.CCR-17-1725. Epub 2018 Jan 19.

4.

Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.

Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, Khiabanian H, Yu J, Waanders E, Iacobucci I, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Kirschner-Schwabe R, Mullighan CG, Rabadan R, Ferrando AA.

Nature. 2018 Jan 25;553(7689):511-514. doi: 10.1038/nature25186. Epub 2018 Jan 17.

5.

Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?

Schwab C, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, Žaliová M, Sutton R, Öfverholm II, Ohki K, Yamashita Y, Groeneveld-Krentz S, Froňková E, Bakkus M, Tchinda J, Barbosa TDC, Fazio G, Mlynarski W, Pastorczak A, Cazzaniga G, Pombo-de-Oliveira MS, Trka J, Kirschner-Schwabe R, Imamura T, Barbany G, Stanulla M, Attarbaschi A, Panzer-Grümayer R, Kuiper RP, den Boer ML, Cavé H, Moorman AV, Harrison CJ, Strehl S.

Blood Adv. 2017 Aug 14;1(19):1473-1477. doi: 10.1182/bloodadvances.2017006734. eCollection 2017 Aug 22.

6.

Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing.

Yu J, Antić Ž, van Reijmersdal SV, Hoischen A, Sonneveld E, Waanders E, Kuiper RP.

Leuk Lymphoma. 2018 Jul;59(7):1690-1699. doi: 10.1080/10428194.2017.1390232. Epub 2017 Oct 23.

PMID:
29058513
7.

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.

Scheijen B, Boer JM, Marke R, Tijchon E, van Ingen Schenau D, Waanders E, van Emst L, van der Meer LT, Pieters R, Escherich G, Horstmann MA, Sonneveld E, Venn N, Sutton R, Dalla-Pozza L, Kuiper RP, Hoogerbrugge PM, den Boer ML, van Leeuwen FN.

Haematologica. 2017 Mar;102(3):541-551. doi: 10.3324/haematol.2016.153023. Epub 2016 Dec 15.

8.

Childhood neuroendocrine tumours: a descriptive study revealing clues for genetic predisposition.

Diets IJ, Nagtegaal ID, Loeffen J, de Blaauw I, Waanders E, Hoogerbrugge N, Jongmans MC.

Br J Cancer. 2017 Jan 17;116(2):163-168. doi: 10.1038/bjc.2016.408. Epub 2016 Dec 13.

9.

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.

Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Wen J, Edmonson M, Payne-Turner D, Kaufmann KB, Takayanagi SI, Wienholds E, Waanders E, Ntziachristos P, Bakogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui CH, Jeha S, Harvey RC, Chen IL, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Mrózek K, Paietta E, Tallman MS, Stock W, Foster MC, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Dick JE, Hunger SP, Loh ML, Downing JR, Mullighan CG; St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project.

Nat Genet. 2016 Dec;48(12):1481-1489. doi: 10.1038/ng.3691. Epub 2016 Oct 24.

10.

Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.

Waanders E, Scheijen B, Jongmans MC, Venselaar H, van Reijmersdal SV, van Dijk AH, Pastorczak A, Weren RD, van der Schoot CE, van de Vorst M, Sonneveld E, Hoogerbrugge N, van der Velden VH, Gruhn B, Hoogerbrugge PM, van Dongen JJ, Geurts van Kessel A, van Leeuwen FN, Kuiper RP.

Leukemia. 2017 Apr;31(4):821-828. doi: 10.1038/leu.2016.277. Epub 2016 Oct 13.

PMID:
27733777
11.

Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool.

Jongmans MC, Loeffen JL, Waanders E, Hoogerbrugge PM, Ligtenberg MJ, Kuiper RP, Hoogerbrugge N.

Eur J Med Genet. 2016 Mar;59(3):116-25. doi: 10.1016/j.ejmg.2016.01.008. Epub 2016 Jan 26. Review.

12.

Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.

Marke R, Havinga J, Cloos J, Demkes M, Poelmans G, Yuniati L, van Ingen Schenau D, Sonneveld E, Waanders E, Pieters R, Kuiper RP, Hoogerbrugge PM, Kaspers GJ, van Leeuwen FN, Scheijen B.

Leukemia. 2016 Jul;30(7):1599-603. doi: 10.1038/leu.2015.359. Epub 2015 Dec 29. No abstract available.

PMID:
26713593
13.

Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels.

Mullighan CG, Jeha S, Pei D, Payne-Turner D, Coustan-Smith E, Roberts KG, Waanders E, Choi JK, Ma X, Raimondi SC, Fan Y, Yang W, Song G, Yang JJ, Inaba H, Downing JR, Leung WH, Bowman WP, Relling MV, Evans WE, Zhang J, Campana D, Pui CH.

Blood. 2015 Dec 24;126(26):2896-9. doi: 10.1182/blood-2015-09-671131. Epub 2015 Nov 2. No abstract available.

14.

Severe Polycystic Liver Disease Is Not Caused by Large Deletions of the PRKCSH Gene.

Cnossen WR, Maurits JS, Salomon J, Te Morsche RH, Waanders E, Drenth JP.

J Clin Lab Anal. 2016 Sep;30(5):431-6. doi: 10.1002/jcla.21875. Epub 2015 Sep 13.

15.

Independent development of lymphoid and histiocytic malignancies from a shared early precursor.

Waanders E, Hebeda KM, Kamping EJ, Groenen PJ, Simons A, Hoischen A, Jongmans MC, Hoogerbrugge PM, van Leeuwen FN, Kuiper RP, Te Loo DM.

Leukemia. 2016 Apr;30(4):955-8. doi: 10.1038/leu.2015.193. Epub 2015 Jul 23. No abstract available.

PMID:
26202925
16.

A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics.

van der Meer LT, Waanders E, Levers M, Venselaar H, Roeleveld D, Boos J, Lanvers C, Brüggemann RJ, Kuiper RP, Hoogerbrugge PM, van Leeuwen FN, te Loo DM.

Blood. 2014 Nov 6;124(19):3027-9. doi: 10.1182/blood-2014-06-582627. No abstract available.

PMID:
25377564
17.

A RAG driver on the road to pediatric ALL.

Kuiper RP, Waanders E.

Nat Genet. 2014 Feb;46(2):96-8. doi: 10.1038/ng.2879.

PMID:
24473322
18.

A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.

Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, Wechsler J, Yang J, Hayes J, Klein RJ, Zhang J, Wei L, Wu G, Rusch M, Nagahawatte P, Ma J, Chen SC, Song G, Cheng J, Meyers P, Bhojwani D, Jhanwar S, Maslak P, Fleisher M, Littman J, Offit L, Rau-Murthy R, Fleischut MH, Corines M, Murali R, Gao X, Manschreck C, Kitzing T, Murty VV, Raimondi S, Kuiper RP, Simons A, Schiffman JD, Onel K, Plon SE, Wheeler D, Ritter D, Ziegler DS, Tucker K, Sutton R, Chenevix-Trench G, Li J, Huntsman DG, Hansford S, Senz J, Walsh T, Lee M, Hahn CN, Roberts K, King MC, Lo SM, Levine RL, Viale A, Socci ND, Nathanson KL, Scott HS, Daly M, Lipkin SM, Lowe SW, Downing JR, Altshuler D, Sandlund JT, Horwitz MS, Mullighan CG, Offit K.

Nat Genet. 2013 Oct;45(10):1226-1231. doi: 10.1038/ng.2754. Epub 2013 Sep 8.

19.

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML.

Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23.

20.

The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution.

Waanders E, Scheijen B, van der Meer LT, van Reijmersdal SV, van Emst L, Kroeze Y, Sonneveld E, Hoogerbrugge PM, van Kessel AG, van Leeuwen FN, Kuiper RP.

PLoS Genet. 2012;8(2):e1002533. doi: 10.1371/journal.pgen.1002533. Epub 2012 Feb 16.

21.

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletion.

Venn NC, van der Velden VH, de Bie M, Waanders E, Giles JE, Law T, Kuiper RP, de Haas V, Mullighan CG, Haber M, Marshall GM, Md N, van Dongen JJ, Sutton R.

Leukemia. 2012 Jun;26(6):1414-6. doi: 10.1038/leu.2011.348. Epub 2011 Dec 9. No abstract available.

22.

Microarray-based genomic profiling as a diagnostic tool in acute lymphoblastic leukemia.

Simons A, Stevens-Kroef M, El Idrissi-Zaynoun N, van Gessel S, Weghuis DO, van den Berg E, Waanders E, Hoogerbrugge P, Kuiper R, van Kessel AG.

Genes Chromosomes Cancer. 2011 Dec;50(12):969-81. doi: 10.1002/gcc.20919. Epub 2011 Aug 31.

PMID:
21882283
23.

Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease.

Janssen MJ, Waanders E, Te Morsche RH, Xing R, Dijkman HB, Woudenberg J, Drenth JP.

Gastroenterology. 2011 Dec;141(6):2056-2063.e2. doi: 10.1053/j.gastro.2011.08.004. Epub 2011 Aug 19.

PMID:
21856269
24.

Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition.

Szczepanski T, van der Velden VH, Waanders E, Kuiper RP, Van Vlierberghe P, Gruhn B, Eckert C, Panzer-Grümayer R, Basso G, Cavé H, Stadt UZ, Campana D, Schrauder A, Sutton R, van Wering E, Meijerink JP, van Dongen JJ.

J Clin Oncol. 2011 Apr 20;29(12):1643-9. doi: 10.1200/JCO.2010.30.2877. Epub 2011 Feb 28.

PMID:
21357790
25.

Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.

Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V, Veerman AJ, van Kessel AG, Hoogerbrugge PM, Kuiper RP, van Dongen JJ.

Leukemia. 2011 Feb;25(2):254-8. doi: 10.1038/leu.2010.275. Epub 2010 Nov 19.

PMID:
21102428
26.

TET2 mutations in childhood leukemia.

Langemeijer SM, Jansen JH, Hooijer J, van Hoogen P, Stevens-Linders E, Massop M, Waanders E, van Reijmersdal SV, Stevens-Kroef MJ, Zwaan CM, van den Heuvel-Eibrink MM, Sonneveld E, Hoogerbrugge PM, van Kessel AG, Kuiper RP.

Leukemia. 2011 Jan;25(1):189-92. doi: 10.1038/leu.2010.243. Epub 2010 Nov 2. No abstract available.

PMID:
21042320
27.

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B, Sonneveld E, van Dongen JJ, Veerman AJ, van Leeuwen FN, van Kessel AG, Hoogerbrugge PM.

Leukemia. 2010 Jul;24(7):1258-64. doi: 10.1038/leu.2010.87. Epub 2010 May 6.

PMID:
20445578
28.

BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia.

van Galen JC, Kuiper RP, van Emst L, Levers M, Tijchon E, Scheijen B, Waanders E, van Reijmersdal SV, Gilissen C, van Kessel AG, Hoogerbrugge PM, van Leeuwen FN.

Blood. 2010 Jun 10;115(23):4810-9. doi: 10.1182/blood-2009-05-223081. Epub 2010 Mar 30.

PMID:
20354172
29.

Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease.

Janssen MJ, Waanders E, Woudenberg J, Lefeber DJ, Drenth JP.

J Hepatol. 2010 Mar;52(3):432-40. doi: 10.1016/j.jhep.2009.12.011. Epub 2009 Dec 24. Review.

30.

Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63.

Waanders E, Venselaar H, te Morsche RH, de Koning DB, Kamath PS, Torres VE, Somlo S, Drenth JP.

Clin Genet. 2010 Jul;78(1):47-56. doi: 10.1111/j.1399-0004.2009.01353.x. Epub 2010 Jan 20.

31.

Comment on: How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?

Waanders E, van Keimpema L, Drenth JP.

Dig Liver Dis. 2010 Mar;42(3):234-5. doi: 10.1016/j.dld.2009.05.020. Epub 2009 Jul 1. No abstract available.

PMID:
19574113
32.

Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease.

Waanders E, van Keimpema L, Brouwer JT, van Oijen MG, Aerts R, Sweep FC, Nevens F, Drenth JP.

Liver Int. 2009 Oct;29(9):1389-95. doi: 10.1111/j.1478-3231.2009.02055.x. Epub 2009 Jun 3.

PMID:
19515221
33.
34.

Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease.

Waanders E, Van Krieken JH, Lameris AL, Drenth JP.

Mod Pathol. 2008 Nov;21(11):1293-302. doi: 10.1038/modpathol.2008.115. Epub 2008 Jun 27.

35.

Hepatocystin is not secreted in cyst fluid of hepatocystin mutant polycystic liver patients.

Waanders E, Lameris AL, Op den Camp HJ, Pluk W, Gloerich J, Strijk SP, Drenth JP.

J Proteome Res. 2008 Jun;7(6):2490-5. doi: 10.1021/pr8000282. Epub 2008 Apr 18.

PMID:
18419150
36.

Cysts of PRKCSH mutated polycystic liver disease patients lack hepatocystin but express Sec63p.

Waanders E, Croes HJ, Maass CN, te Morsche RH, van Geffen HJ, van Krieken JH, Fransen JA, Drenth JP.

Histochem Cell Biol. 2008 Mar;129(3):301-10. doi: 10.1007/s00418-008-0381-3. Epub 2008 Jan 26.

PMID:
18224332
37.

Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease.

Waanders E, te Morsche RH, de Man RA, Jansen JB, Drenth JP.

Hum Mutat. 2006 Aug;27(8):830.

PMID:
16835903
38.

On the monophyly of chromalveolates using a six-protein phylogeny of eukaryotes.

Harper JT, Waanders E, Keeling PJ.

Int J Syst Evol Microbiol. 2005 Jan;55(Pt 1):487-96.

PMID:
15653923
39.

Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time.

Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, Beex LV, Sweep FC.

J Clin Oncol. 2004 Feb 15;22(4):691-8.

PMID:
14966093
40.

Mutation analysis of the entire keratin 5 and 14 genes in patients with epidermolysis bullosa simplex and identification of novel mutations.

Schuilenga-Hut PH, Vlies Pv, Jonkman MF, Waanders E, Buys CH, Scheffer H.

Hum Mutat. 2003 Apr;21(4):447. Review.

PMID:
12655565

Supplemental Content

Loading ...
Support Center